Pharma feed

N
Ministry of Health, Labour and Welfare
Bristol-Myers Squibb· 20 Jan 2022

Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan

TOKYO, January 20, 2022 -- Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (i decabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell

  • Regulatory and Legal
  • KK Group
  • Ministry of Health, Labour and Welfare
  • Bristol-Myers Squibb Co
  • Company Websites
  • Press Releases
N
Pfizer Inc
Syapse· 20 Jan 2022

​Syapse Extends Collaboration with Pfizer to Continue to…

SAN FRANCISCO, January 20, 2022 -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced that Pfizer will continue working with Syapse to advance the use of real-world data (RWD) from the Syapse Learning Health Network™ (LHN), as an extension of the organizations’ ongoing collaboration.

  • Partnerships and Alliances
  • Pfizer Inc
  • Syapse, Inc.
  • SAP SE
  • Company Websites
  • Press Releases
N
Takeda Pharmaceutical Co Ltd
Takeda· 20 Jan 2022

Takeda Named Global Top Employer for Fifth Consecutive Year

OSAKA, Japan and CAMBRIDGE, Massachusetts, January 19, 2022 – Takeda Pharmaceutical Company Limited ( ) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide.

  • Awards and Recognitions
  • Takeda Pharmaceutical Co Ltd
  • Company Websites
  • Press Releases
N
GlaxoSmithKline PLC
GSK· 19 Jan 2022

Tony Wood appointed Chief Scientific Officer designate, GSK

19 January 2022 Issued: London UK GlaxoSmithKline plc (GSK) today announced the appointment of Tony Wood as Chief Scientific Officer (CSO) designate. Tony will assume full accountability for Research and Development (R&D) from current CSO, Dr Hal Barron, on 1 August 2022, after which Hal will remain on GSK’s Board and become a Non-Executive Director, with additional responsibilities to support R&D.

  • Management Changes
  • GlaxoSmithKline PLC
  • Company Websites
  • News Articles
N
GlaxoSmithKline PLC
The Economic Times· 19 Jan 2022

GSK to increase Covid drug capacity, but no plans for India yet

British drugmaker GSK said it is actively working to expand supply of its Covid-19 monoclonal antibody medication Sotrovimab, to make it available to more patients. "We remain committed to partnering with governments around the world to provide Sotrovimab as a tool in response to the ongoing pandemic," GSK India spokesperson told ET in a statement.

  • Business Expansion
  • Partnerships and Alliances
  • GlaxoSmithKline PLC
  • News Websites
  • News Articles
N
Eli Lilly and Co
Pharmabiz· 19 Jan 2022

Evotec enters drug discovery collaboration with Eli Lilly in the field of metabolic diseases

Evotec SE announced that the company has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention.

  • Partnerships and Alliances
  • Eli Lilly and Co
  • Evotec AG
  • News Websites
  • News Articles
N
Teva Pharmaceutical Industries Ltd
Yahoo· 18 Jan 2022

Teva settles shareholder lawsuit over generic drug pricing for $420 million

By Jody Godoy(Reuters) -Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.The settlement was disclosed on Tuesday in papers filed in federal court in Connecticut.

  • Regulatory and Legal
  • Negative News
  • Teva Pharmaceutical Industries Ltd
  • News Websites
  • News Articles
N
Hoffmann-La Roche Ltd
Seeking Alpha· 17 Jan 2022

Roche Holding awarded $340M army contract

Roche Diagnostics (OTCQX:RHHBY) was awarded a $340M firm-fixed-price contract for COVID-19 rapid antigen tests. Work will be performed in Indianapolis, Indiana, with an estimated completion date of March 14, 2022.

  • Procurement and Sales
  • Hoffmann-La Roche Ltd
  • Roche Diagnostics
  • News Websites
  • News Articles
N
GlaxoSmithKline PLC
Foodnavigator· 17 Jan 2022

‘Rotation of our portfolio is part of upgrading into higher growth spaces’: Unilever hints at food operation sell offs

GSK confirmed Unilever had approached it with three proposals, the most recent being £50 billion, which GSK said“fundamentally undervalued”​ the division.In the update this morning (17 January), Unilever confirmed GSK’s consumer healthcare division would be “a strong strategic fit”.

  • M&A Activities
  • GlaxoSmithKline PLC
  • Unilever PLC
  • News Websites
  • News Articles
N
Novartis AG
Tenders Info· 15 Jan 2022

Switzerland: Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function

Agreement will bring Alnylams proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver

  • Partnerships and Alliances
  • Function Group
  • Novartis AG
  • Licensed Content
  • News Articles
N
GlaxoSmithKline PLC
GSK· 15 Jan 2022

Update - GSK Consumer Healthcare

15 January 2022 Issued: London UK GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of £50 billion comprising £41.7 billion in cash and £8.3 billion in Unilever shares.

  • M&A Activities
  • GlaxoSmithKline PLC
  • GlaxoSmithKline Consumer Healthcare Ltd
  • GlaxoSmithKline Consumer Healthcare Pakistan Limited
  • Company Websites
  • Press Releases
N
Allergan Inc
Abbvie· 14 Jan 2022

U.S. FDA Approves RINVOQ (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

AbbVie announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ(upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.

  • Regulatory and Legal
  • Allergan Inc
  • US Food and Drug Administration
  • AbbVie Inc
  • Company Websites
  • Press Releases
N
Johnson & Johnson
Johnson & Johnson· 14 Jan 2022

Johnson & Johnson Statement on New Mexico Opioid Settlement Agreement

Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies announced a settlement agreement with the State of New Mexico and its participating subdivisions resolving their opioid-related claims against the Company. With this agreement, the Company is removed from pending litigation by the State and its subdivisions.

  • Procurement and Sales
  • Johnson & Johnson
  • Janssen Pharmaceuticals Inc
  • Company Websites
  • Press Releases
N
Novartis AG
Drug Store News· 13 Jan 2022

U.S. Court of Appeals for the Federal Circuit upholds validity of Novartis’ Gilenya dosage regimen patent

Novartis announced that the U.S. Court of Appeals for the Federal Circuit issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing regimen for Gilenya. In August 2020, the U.S. Federal District Court for the District of Delaware issued a favorable decision in the Gilenya patent litigation and a permanent injunction was granted against HEC Pharma until the expiration of the ‘405 patent in December 2027 (including pediatric exclusivity).

  • Regulatory and Legal
  • Novartis AG
  • HEC Pharma Co., Ltd
  • News Websites
  • News Articles
N
US Food and Drug Administration
Pharmafile· 12 Jan 2022

Novartis to seek FDA Emergency Use Approval approval for new COVID-19 therapy

Novartis shared on the 10 January, that positive data from a clinical trial of COVID-19 therapeutic drug ensovibep, has prompted the firm to exercise an option to in-license the antiviral from development partner Molecular Partners, and later seek emergency use approval from US regulators.

  • Regulatory and Legal
  • US Food and Drug Administration
  • Novartis AG
  • News Websites
  • News Articles
N
Digital Surgery
Becker's Hospital Review· 12 Jan 2022

J&J partners with Microsoft for digital surgery solutions

Johnson & Johnson has teamed up with Microsoft to help build a cloud-connected software system for its digital surgery solutions. Mixing artificial intelligence, machine learning, Johnson & Johnson hopes this partnership with the tech giant will help it put data on a unified cloud, according to a Jan.

  • Partnerships and Alliances
  • Artificial Intelligence
  • Digital Surgery
  • Microsoft Corporation
  • Johnson & Johnson
  • Jj Partners Inc
  • News Websites
  • News Articles
N
US Food and Drug Administration
Healtheconomics· 10 Jan 2022

FDA Approves New Heart Drug by Novartis

Novartis’s genetic drug Levqio was approved by the FDA in December, but hurdles remain for long-term sales. The drug, which dramatically reduces bad cholesterol from the blood with only two injections per year, is similar to other recently released drugs to middling sales.

  • Regulatory and Legal
  • US Food and Drug Administration
  • Novartis AG
  • News Websites
  • News Articles
N
Dana Incorporated
Askbio· 10 Jan 2022

AskBio Names Philip Dana Chief Human Resources Officer

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2022 /PRNewswire/ — Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Philip Dana has been appointed to its executive team as Chief Human Resources Officer.

  • Management Changes
  • Asklepios BioPharmaceutical Inc
  • Dana Incorporated
  • Bayer AG
  • Company Websites
  • Press Releases
N
JPMorgan Chase & Co.
Bristol-Myers Squibb· 10 Jan 2022

Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) will highlight progress against the Company’s growth strategy and outlook for 2022 during a presentation scheduled today at 7:30 a.m. ET at the 40 th Annual J.P. Morgan Healthcare Conference.

  • Financial Results
  • Events
  • JPMorgan Chase & Co.
  • Bristol-Myers Squibb Co
  • Company Websites
  • Press Releases
N
Takeda Pharmaceutical Co Ltd
Takeda· 10 Jan 2022

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel GammaDelta (γδ) T Cell Engager Therapies Targeting Solid Tumors

OSAKA, Japan, and LONDON, UK. January 10 , 2022 – Takeda Pharmaceutical Company Limited ( ) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.

  • M&A Activities
  • Takeda Pharmaceutical Co Ltd
  • Company Websites
  • Press Releases
N
Novartis AG
PharmTech· 10 Jan 2022

Novartis and Alnylam Announce Liver Therapy Collaboration

On Jan. 6, 2022, Novartis and Alnylam announced a therapeutic development collaboration aimed toward treating end-stage liver disease (ESLD). The companies will use Alynlam’s proprietary small interfering RNA (siRNA) technology to inhibit a target discovered by Novartis.

  • Partnerships and Alliances
  • Novartis AG
  • News Websites
  • News Articles
N
Novartis AG
Medical Dialogues· 08 Jan 2022

Novartis gets CDSCO panel nod to study Alpelisib for early (prophylactic) and sustained improvement of hyperglycemia

New Delhi: Pharmaceutical major Novartis has got a conditional nod from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct the phase II trial of Alpelisib to investigate the management strategies that offer earlier (prophylactic) and sustained improvement of hyperglycemia than what is achieved with Metformin and/or Dapagliflozin as initial therapy after hyperglycemia has been observed.

  • Regulatory and Legal
  • Novartis AG
  • News Websites
  • News Articles
N
Novartis AG
Medical Dialogues· 07 Jan 2022

Novartis gets CDSCO panel nod to study Ligelizumab in treatment of chronic inducible urticaria

New Delhi: Pharma major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of Ligelizumab in the treatment of chronic inducible urticaria (CINDU) in adolescents and adults inadequately controlled with H1-Anti Histamines.

  • Regulatory and Legal
  • Central Drugs Standard Control Organization
  • Novartis AG
  • News Websites
  • News Articles
N
Informa PLC
Scrip· 06 Jan 2022

Novartis Opts For Alliance Rather Than Acquisition With Alnylam

The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.

  • M&A Activities
  • Partnerships and Alliances
  • Informa PLC
  • Novartis AG
  • Company Websites
  • News Articles
N
Novartis AG
Silicon Republic· 06 Jan 2022

Dublin is now a ‘leading digital science centre’ for pharma giant Novartis

Novartis’s Ciara O’Connell discusses the role of data in pharma and how the company is tapping into Ireland’s ‘significant tech ecosystem’. Ciara O’Connell is head of the Novartis Global Service Centre (NGSC) in Ireland. This was set up in 2013 and is now one of five sites worldwide delivering a variety of services to the multinational pharma company in areas such as AI and data.

  • Artificial Intelligence
  • Novartis AG
  • Digital Science
  • News Websites
  • News Articles
1